tiprankstipranks
Assembly Biosciences (DE:V7B)
FRANKFURT:V7B
Germany Market
V7B
Assembly Biosciences
RESEARCH TOOLSreports

Assembly Biosciences (V7B) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

V7B Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Assembly
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

V7B Stock 12 Month Forecast

Average Price Target

€42.64
▲(48.05% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Assembly Biosciences in the last 3 months. The average price target is €42.64 with a high forecast of €45.65 and a low forecast of €37.04. The average price target represents a 48.05% change from the last price of €28.80.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"€19","46":"€46","25.75":"€25.8","32.5":"€32.5","39.25":"€39.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45.65207099,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€45.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.637311585,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€42.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.03847269,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€37.04</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,25.75,32.5,39.25,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.1,30.37323623,31.646472460000002,32.91970869,34.19294492,35.46618115,36.73941738,38.01265361,39.285889839999996,40.55912607,41.8323623,43.105598529999995,44.37883476,{"y":45.65207099,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.1,30.141331660384616,31.182663320769233,32.22399498115385,33.265326641538465,34.30665830192308,35.34798996230769,36.38932162269231,37.43065328307692,38.471984943461536,39.51331660384615,40.55464826423077,41.595979924615385,{"y":42.637311585,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.1,29.710651745384617,30.321303490769232,30.931955236153847,31.542606981538462,32.15325872692308,32.76391047230769,33.37456221769231,33.98521396307692,34.59586570846154,35.20651745384615,35.81716919923077,36.427820944615384,{"y":37.03847269,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.15,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.1,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€45.65Average Price Target€42.64Lowest Price Target€37.04
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on DE:V7B
Ashwani Verma
UBS
UBS
€44.79
Buy
55.52%
Upside
Initiated
09/01/26
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (NASDAQ: TEM) and Assembly Biosciences (NASDAQ: ASMB)
Mizuho Securities Analyst forecast on DE:V7B
Salim Syed
Mizuho Securities
Mizuho Securities
€38.76→€45.65
Buy
58.51%
Upside
Reiterated
08/31/26
Assembly Biosciences (ASMB) Receives a Buy from Mizuho Securities
H.C. Wainwright Analyst forecast on DE:V7B
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
€43.07
Buy
49.54%
Upside
Reiterated
08/18/26
Assembly Biosciences: Strategic Pipeline Expansion, Strong Cash Position Support Unchanged $50 Price Target and Buy Rating
Guggenheim Analyst forecast on DE:V7B
Vamil Divan
Guggenheim
Guggenheim
€37.04
Buy
28.61%
Upside
Reiterated
08/16/26
Guggenheim Keeps Their Buy Rating on Assembly Biosciences (ASMB)
Citizens JMP Analyst forecast on DE:V7B
Roy Buchanan
Citizens JMP
Citizens JMP
€32.73
Buy
13.65%
Upside
Initiated
09/24/25
Assembly Biosciences initiated with an Outperform at Citizens JMPAssembly Biosciences initiated with an Outperform at Citizens JMP
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on DE:V7B
Ashwani Verma
UBS
UBS
€44.79
Buy
55.52%
Upside
Initiated
09/01/26
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (NASDAQ: TEM) and Assembly Biosciences (NASDAQ: ASMB)
Mizuho Securities Analyst forecast on DE:V7B
Salim Syed
Mizuho Securities
Mizuho Securities
€38.76→€45.65
Buy
58.51%
Upside
Reiterated
08/31/26
Assembly Biosciences (ASMB) Receives a Buy from Mizuho Securities
H.C. Wainwright Analyst forecast on DE:V7B
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
€43.07
Buy
49.54%
Upside
Reiterated
08/18/26
Assembly Biosciences: Strategic Pipeline Expansion, Strong Cash Position Support Unchanged $50 Price Target and Buy Rating
Guggenheim Analyst forecast on DE:V7B
Vamil Divan
Guggenheim
Guggenheim
€37.04
Buy
28.61%
Upside
Reiterated
08/16/26
Guggenheim Keeps Their Buy Rating on Assembly Biosciences (ASMB)
Citizens JMP Analyst forecast on DE:V7B
Roy Buchanan
Citizens JMP
Citizens JMP
€32.73
Buy
13.65%
Upside
Initiated
09/24/25
Assembly Biosciences initiated with an Outperform at Citizens JMPAssembly Biosciences initiated with an Outperform at Citizens JMP
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
BLTEBelite Bio, Inc. ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Assembly Biosciences

3 Months
Patrick TrucchioH.C. Wainwright
Success Rate
4/10 ratings generated profit
40%
Average Return
+2.30%
Copying Patrick Trucchio's trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +2.30% per trade.
1 Year
Patrick TrucchioH.C. Wainwright
Success Rate
9/10 ratings generated profit
90%
Average Return
+15.81%
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +15.81% per trade.
2 Years
Patrick TrucchioH.C. Wainwright
Success Rate
9/10 ratings generated profit
90%
Average Return
+16.56%
Copying Patrick Trucchio's trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +16.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

V7B Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
6
7
6
4
3
Buy
3
2
1
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
9
7
5
4
In the current month, V7B has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. V7B average Analyst price target in the past 3 months is 42.64.
Each month's total comprises the sum of three months' worth of ratings.

V7B Financial Forecast

V7B Earnings Forecast

Next quarter’s earnings estimate for V7B is -€0.56 with a range of -€0.96 to -€0.22. The previous quarter’s EPS was -€0.17. V7B beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year V7B has Performed in-line its overall industry.
Next quarter’s earnings estimate for V7B is -€0.56 with a range of -€0.96 to -€0.22. The previous quarter’s EPS was -€0.17. V7B beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year V7B has Performed in-line its overall industry.

V7B Sales Forecast

Next quarter’s sales forecast for V7B is €7.82M with a range of €4.31M to €10.77M. The previous quarter’s sales results were €11.52M. V7B beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year V7B has Performed in-line its overall industry.
Next quarter’s sales forecast for V7B is €7.82M with a range of €4.31M to €10.77M. The previous quarter’s sales results were €11.52M. V7B beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year V7B has Performed in-line its overall industry.

V7B Stock Forecast FAQ

What is DE:V7B’s average 12-month price target, according to analysts?
Based on analyst ratings, Assembly Biosciences’s 12-month average price target is 42.64.
    What is DE:V7B’s upside potential, based on the analysts’ average price target?
    Assembly Biosciences has 48.05% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Assembly Biosciences a Buy, Sell or Hold?
          Assembly Biosciences has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Assembly Biosciences’s share price target?
            The average share price target for Assembly Biosciences is 42.64. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €45.65 ,and the lowest forecast is €37.04. The average share price target represents 48.05% Increase from the current price of €28.8.
              What do analysts say about Assembly Biosciences?
              Assembly Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of Assembly Biosciences?
                To buy shares of DE:V7B, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.